Suppr超能文献

癫痫患者中丙戊酸钠血浆蛋白结合的剂量内变异

Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients.

作者信息

Marty J J, Kilpatrick C J, Moulds R F

出版信息

Br J Clin Pharmacol. 1982 Sep;14(3):399-404. doi: 10.1111/j.1365-2125.1982.tb01998.x.

Abstract

1 The fluctuations in protein binding of sodium valproate during one dosing interval were studied in five patients stabilized on valproate and taking concurrent anticonvulsant therapy. 2 The patients took their usual morning dose of valproate (400-800 mg) and serial blood samples were collected by venepuncture at 0, 1, 2, 3, 4, and 6 h post-dose. 3 Free valproate was separated from protein bound drug by plasma ultrafiltration and the ultrafiltrate and total plasma valproate concentrations were measured by a gas chromatographic method. 4 The maximum and minimum concentrations in the ultrafiltrates occurred at the same times as in the plasma. However, the percentage fluctuation was always greater in the ultrafiltrates (range 192-412%) compared with the plasma (range 153-374%) due to the concentration-dependent nature of valproate protein binding. 5 If free valproate levels are to be monitored, knowledge of sampling time and dosage history is important for interpretation of the results.

摘要
  1. 研究了5名服用丙戊酸钠并同时接受抗惊厥治疗的稳定患者在一个给药间隔期内丙戊酸钠蛋白结合的波动情况。

  2. 患者服用其常用的早晨剂量丙戊酸钠(400 - 800毫克),并在给药后0、1、2、3、4和6小时通过静脉穿刺采集系列血样。

  3. 通过血浆超滤将游离丙戊酸与蛋白结合药物分离,并用气相色谱法测定超滤液和总血浆丙戊酸浓度。

  4. 超滤液中的最大和最小浓度与血浆中的出现时间相同。然而,由于丙戊酸蛋白结合的浓度依赖性,超滤液中的波动百分比总是大于血浆中的波动百分比(范围为192 - 412%),而血浆中的波动百分比范围为153 - 374%。

  5. 如果要监测游离丙戊酸水平,了解采样时间和用药史对于结果的解释很重要。

相似文献

1
Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients.
Br J Clin Pharmacol. 1982 Sep;14(3):399-404. doi: 10.1111/j.1365-2125.1982.tb01998.x.
4
Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.
Br Med J (Clin Res Ed). 1982 Jan 2;284(6308):13-6. doi: 10.1136/bmj.284.6308.13.
7
Plasma concentrations of unbound valproate and the management of epilepsy.
Aust N Z J Med. 1987 Dec;17(6):574-9. doi: 10.1111/j.1445-5994.1987.tb01259.x.
8
Valproic acid dosage and plasma protein binding and clearance.
Clin Pharmacol Ther. 1980 Oct;28(4):486-92. doi: 10.1038/clpt.1980.192.
9
Monitoring phenytoin in salivary and plasma ultrafiltrates of pediatric patients.
Ther Drug Monit. 1983;5(3):325-9. doi: 10.1097/00007691-198309000-00014.
10
Effect of valproate on free plasma phenytoin concentrations.
Br J Clin Pharmacol. 1984 Jul;18(1):17-20. doi: 10.1111/j.1365-2125.1984.tb05015.x.

引用本文的文献

2
Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing.
Br J Clin Pharmacol. 1983 Oct;16(4):365-9. doi: 10.1111/j.1365-2125.1983.tb02179.x.
4
Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.
Br J Clin Pharmacol. 1988 Jan;25(1):59-66. doi: 10.1111/j.1365-2125.1988.tb03282.x.

本文引用的文献

1
Monitoring of free valproic acid levels?
Ther Drug Monit. 1980;2(2):199-201. doi: 10.1097/00007691-198004000-00015.
2
Therapeutic monitoring of valproic acid.
Ther Drug Monit. 1980;2(1):61-71. doi: 10.1097/00007691-198001000-00008.
6
Valproic acid dosage and plasma protein binding and clearance.
Clin Pharmacol Ther. 1980 Oct;28(4):486-92. doi: 10.1038/clpt.1980.192.
7
Protein binding of valproic acid in uremic patients.
Neurology. 1980 May;30(5):557-9. doi: 10.1212/wnl.30.5.557-a.
8
Clinical pharmacokinetics of valproic acid.
Clin Pharmacokinet. 1980 Jan-Feb;5(1):67-83. doi: 10.2165/00003088-198005010-00002.
9
Sodium valproate in treatment of epilepsy.
Br Med J. 1974 Jun 15;2(5919):584-6. doi: 10.1136/bmj.2.5919.584.
10
Valproic acid: reversibly acting drug?
Epilepsia. 1976 Dec;17(4):477-9. doi: 10.1111/j.1528-1157.1976.tb04459.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验